Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ICCC
BUYImmuCell Corporation · Healthcare · United States · $100M · Avg Vol: $345K/d
78
StockRankGet insider-trade alerts
Q
60
V
36
M
76
P/E (TTM)
—
ROE
-1.9%
D/E
0.4x
Dividend %
—
Loading 1Y...
PRICE (1Y)+13.2%
SMA 50SMA 200
Close
$11.03
RSI (14)
60.5
52W High
$12.10
From 52W High
0.9%
SCORE BREAKDOWN
Quality
60
ROIC
-0.2%45.7
ROE
-1.9%43.9
GP/Assets
30.0%66.6
Op. Margin
19.0%81.8
FCF/Assets
7.9%80.3
Piotroski
376.1
Int. Cover
-0.2x36.9
D/E Ratio
0.44x33.2
Current Ratio
4.82x70.0
Value
36
P/E (TTM)
—N/A
EV/EBITDA
18.0x35.2
P/FCF
29.6x43.3
P/B
3.4x38.9
P/S
3.3x53.4
Div Yield
—N/A
Momentum
76
52W High %
91%88.6
RS 6M
60%95.4
SMA 50/200
1.38x96.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-57%8.7
Q Growth
34%69.7
FUNDAMENTALS
Market Cap
$100M
P/E (Forward)
-100.3x
Gross Margin
42.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ICCC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ICCC | ImmuCell Corporation(you) | $100M | 78 | BUY |
| SPRO | Spero Therapeutics, Inc. | $69M | 71 | BUY |
| FBIO | Fortress Biotech, Inc. | $111M | 60 | HOLD |
| CSBR | Champions Oncology, Inc. | $85M | 58 | HOLD |
| NAGE | Niagen Bioscience, Inc. | $256M | 73 | BUY |
| ORMP | Oramed Pharmaceuticals Inc. | $165M | 58 | HOLD |
| PLX | Protalix BioTherapeutics, Inc. | $191M | 99 | STRONG BUY |
| AGEN | Agenus Inc. | $249M | 61 | HOLD |
| ZVRA | Zevra Therapeutics, Inc. | $563M | 81 | STRONG BUY |
| MDXG | MiMedx Group, Inc. | $626M | 75 | BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%